UNSPSC 51363501: Amobarbital/secobarbital

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN301. This VA Drug Class (CN301) classifies this compound as belonging to the group BARBITURIC ACID DERIVATIVE SEDATIVES/HYPNOTICS.

UNSPSC 51363501 Amobarbital/secobarbital is a Commodity code that in practice captures barbiturate pharmaceuticals and related controlled substances procured by state and local health and human services agencies. Recent solicitations show minimal direct procurement of the named barbiturate itself; instead, the code appears to tag broader pharmaceutical supply agreements that include barbiturates as line items within generic multi-source pharmaceutical catalogs or opioid-response initiatives. State and local governments use this code to source pharmaceutical inventory through cooperative purchasing vehicles, direct manufacturer relationships, and wholesaler-mediated supply chains. Issuing bodies include state health departments, county health systems, and multistate cooperative purchasing alliances. Seminole County, Florida and the Minnesota Department of Administration (through its multistate cooperative MMCAP) are active buyers in this space.

Recent opportunities span Florida and Minnesota through multistate purchasing vehicles. Seminole County issued IFB 60459723LAS in June 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a July 26, 2023 response deadline, reflecting community health and opioid-response procurement aligned with this commodity family. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, released an RFP (S1070000015802) in January 2026 with a March 26, 2026 response deadline for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities in Minnesota and Oregon, requiring vendors to work through three authorized wholesalers and certify compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act. The Texas Health and Human Services Commission issued an exploratory RFI (HHS0017013) in April 2026 to evaluate direct-to-manufacturer prescription programs, signaling emerging interest in supply-chain alternatives beyond traditional pharmacy benefit manager models.